Alivus Life Sciences FY26 PAT Rises 16.2% to ₹5,645 Mn; ₹5

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its audited financial results for the quarter and year ended March 31, 2026, approved by the Board of Directors at its meeting held on May 14, 2026. The company reported broad-based financial improvement across revenue, margins, and profitability for both the quarter and the full fiscal year, supported by strong momentum in its Non-GPL business and a CDMO turnaround in the second half. The Board also recommended a final equity dividend of ₹5 per share (250%) for FY26, subject to shareholder approval at the ensuing Annual General Meeting.

Q4FY26 & FY26 Financial Highlights

For FY26, Alivus registered Revenue from operations of ₹25,518 Mn, a growth of 6.9% year-on-year. For Q4FY26, Revenue from operations was ₹6,891 Mn, a growth of 6.1% year-on-year. EBITDA for FY26 was at ₹8,577 Mn, a growth of 19.6% year-on-year, with EBITDA margins at 33.6%, up 360 basis points YoY. For Q4FY26, EBITDA was at ₹2,373 Mn, a growth of 13.8% year-on-year, with margins at 34.4%, up 230 basis points YoY.

PAT for FY26 stood at ₹5,645 Mn, a growth of 16.2% year-on-year, with PAT margins at 22.1%, up 180 basis points YoY. PAT for Q4FY26 stood at ₹1,627 Mn, a growth of 14.7% year-on-year, with margins at 23.6%, up 180 basis points YoY. During FY26, the company generated a strong free cash flow of ₹2,590 Mn, leading to Cash and Cash Equivalents (including short-term investments) of ₹7,824 Mn as of March 31, 2026. The following table summarises the key quarterly and annual financial metrics:

Particulars (In ₹ Million): Q4FY26 Q3FY26 QoQ Q4FY25 YoY FY26 FY25 YoY Revenue from Operations: 6,891 6,729 2.4% 6,496 6.1% 25,518 23,869 6.9% Gross Profit: 4,182 3,965 5.5% 3,670 14.0% 14,853 13,061 13.7% Gross Profit (%): 60.7% 58.9% +180 bps 56.5% +420 bps 58.2% 54.7% +350 bps EBITDA: 2,373 2,452 -3.2% 2,085 13.8% 8,577 7,172 19.6% EBITDA Margin (%): 34.4% 36.4% -200 bps 32.1% +230 bps 33.6% 30.0% +360 bps PBT (before exceptional items): 2,158 2,241 -3.7% 1,913 12.8% 7,771 6,542 18.8% PAT: 1,627 1,503 8.3% 1,419 14.7% 5,645 4,857 16.2% Net Margin (%): 23.6% 22.3% +130 bps 21.8% +180 bps 22.1% 20.3% +180 bps

Earnings Per Share & Dividend

The Board of Directors recommended a final dividend of ₹5 per equity share of face value ₹2 each (250%) for FY26, subject to shareholder approval at the ensuing Annual General Meeting. The audited results carry an unmodified opinion from statutory auditors Walker Chandiook & Co LLP. The following table presents the earnings per share metrics:

Metric: Q4FY26 Q3FY26 Q4FY25 FY26 FY25 Basic EPS (₹): 13.23 12.25 11.57 45.99 39.63 Diluted EPS (₹): 13.22 12.22 11.55 45.90 39.52 Paid-up Equity Share Capital (₹ Mn): 245.47 245.36 245.07 245.47 245.07

Balance Sheet Highlights

As at March 31, 2026, Alivus reported Total Assets of ₹39,828.97 Mn compared to ₹34,114.53 Mn a year earlier. Total Equity stood at ₹33,321.32 Mn, up from ₹28,173.72 Mn. Non-Current Assets grew to ₹13,335.37 Mn from ₹10,762.95 Mn, reflecting ongoing capital expenditure including Solapur Phase 1 and 1.1 construction. Investment in Mutual Funds (current) stood at ₹7,803.79 Mn as at March 31, 2026. The company maintained a debt-free balance sheet with Other Equity of ₹33,075.85 Mn. The following table presents a summary of the balance sheet:

Particulars (₹ Mn): 31st March 2026 31st March 2025 Total Non-Current Assets: 13,335.37 10,762.95 Total Current Assets: 26,493.60 23,351.58 Total Assets: 39,828.97 34,114.53 Total Equity: 33,321.32 28,173.72 Total Non-Current Liabilities: 1,427.30 1,239.22 Total Current Liabilities: 5,080.35 4,701.59 Total Liabilities: 6,507.65 5,940.81

Cash Flow Summary

For FY26, Net Cash Generated from Operating Activities was ₹5,654.13 Mn, compared to ₹3,915.24 Mn in FY25. Net Cash used in Investing Activities was ₹5,701.53 Mn, driven primarily by capital expenditure of ₹3,070.55 Mn and investment in Fixed Deposits/Mutual Funds of ₹4,950.03 Mn, partially offset by redemption of Mutual Funds of ₹2,302.92 Mn. Net Cash used in Financing Activities was ₹643.40 Mn, which included dividend paid of ₹613.41 Mn. The closing balance of Cash and Cash Equivalents stood at ₹19.82 Mn as at March 31, 2026.

Particulars (₹ Mn): FY26 FY25 Net Cash from Operating Activities: 5,654.13 3,915.24 Net Cash used in Investing Activities: (5,701.53) (6,156.45) Net Cash used in Financing Activities: (643.40) (62.31) Closing Cash & Cash Equivalents: 19.82 710.62

Management Commentary

Dr. Yasir Rawjee, MD & CEO, stated that FY26 reflected a clear improvement in operating performance, with revenue growing 6.9% year-on-year supported by 13% growth in the non-GPL business. The CDMO business delivered a planned turnaround in the second half, closing the year with 18% YoY growth. He expressed confidence in delivering high single-digit revenue growth for FY27, with margins sustained above 30%.

Tushar Mistry, CFO, highlighted that the company ended FY26 with 6.9% growth and EBITDA margins of 33.6%, exceeding the guided range of 30–32%. He attributed the performance to a favourable product mix and disciplined control over operating expenses, noting strong operating cash flows that provide flexibility for growth initiatives while maintaining a healthy, debt-free balance sheet.

Business Segment and Operational Updates

The Generic API segment contributed 93% of total revenue in Q4FY26, recording revenue of ₹6,343 Mn. The CDMO segment, contributing 7% of the total portfolio in FY26, posted revenue of ₹453 Mn in Q4FY26. On a full-year basis, the CDMO business delivered 18% year-on-year growth. The Non-GPL business grew 13% for the full year FY26, now contributing 71% of total revenues.

DMF / CEP filings continue across major markets, taking the total cumulative filings to 611 as of March 31, 2026. The HP API portfolio has 28 APIs in the active grid, with 12 products validated and seven products in advanced stages of development. Solapur Phase 1 and 1.1 construction work is in progress for 465 KL capacity. The company has also acquired land in Taloja (Navi Mumbai) admeasuring 10,000 square meters to establish a state-of-the-art R&D centre.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.